Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial
<p><strong>Background:</strong><br /> There is increasing interest in the timely administration of concentrated sources of fibrinogen to patients with major traumatic bleeding. Following evaluation of early cryoprecipitate in the CRYOSTAT 1 trial, we explored the use of fibri...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2018
|
| _version_ | 1797068729354289152 |
|---|---|
| author | Curry, N Foley, C Wong, H Mora, A Curnow, E Zarankaite, A Hodge, R Hopkins, V Deary, A Ray, J Moss, P Reed, MJ Kellett, S Davenport, R Stanworth, S |
| author_facet | Curry, N Foley, C Wong, H Mora, A Curnow, E Zarankaite, A Hodge, R Hopkins, V Deary, A Ray, J Moss, P Reed, MJ Kellett, S Davenport, R Stanworth, S |
| author_sort | Curry, N |
| collection | OXFORD |
| description | <p><strong>Background:</strong><br />
There is increasing interest in the timely administration of concentrated sources of fibrinogen to patients with major traumatic bleeding. Following evaluation of early cryoprecipitate in the CRYOSTAT 1 trial, we explored the use of fibrinogen concentrate, which may have advantages of more rapid administration in acute haemorrhage. The aims of this pragmatic study were to assess the feasibility of fibrinogen concentrate administration within 45 minutes of hospital admission and to quantify efficacy in maintaining fibrinogen levels ≥ 2 g/L during active haemorrhage.</p><br />
<p><strong>Methods:</strong><br />
We conducted a blinded, randomised, placebo-controlled trial at five UK major trauma centres with adult trauma patients with active bleeding who required activation of the major haemorrhage protocol. Participants were randomised to standard major haemorrhage therapy plus 6 g of fibrinogen concentrate or placebo.</p><br />
<p><strong>Results:</strong><br />
Twenty-seven of 39 participants (69%; 95% CI, 52–83%) across both arms received the study intervention within 45 minutes of admission. There was some evidence of a difference in the proportion of participants with fibrinogen levels ≥ 2 g/L between arms (p = 0.10). Fibrinogen levels in the fibrinogen concentrate (FgC) arm rose by a mean of 0.9 g/L (SD, 0.5) compared with a reduction of 0.2 g/L (SD, 0.5) in the placebo arm and were significantly higher in the FgC arm (p < 0.0001) at 2 hours. Fibrinogen levels were not different at day 7. Transfusion use and thromboembolic events were similar between arms. All-cause mortality at 28 days was 35.5% (95% CI, 23.8–50.8%) overall, with no difference between arms.</p><br />
<p><strong>Conclusions:</strong><br />
In this trial, early delivery of fibrinogen concentrate within 45 minutes of admission was not feasible. Although evidence points to a key role for fibrinogen in the treatment of major bleeding, researchers need to recognise the challenges of timely delivery in the emergency setting. Future studies must explore barriers to rapid fibrinogen therapy, focusing on methods to reduce time to randomisation, using ‘off-the-shelf’ fibrinogen therapies (such as extended shelf-life cryoprecipitate held in the emergency department or fibrinogen concentrates with very rapid reconstitution times) and limiting the need for coagulation test-based transfusion triggers.</p><br />
<p><strong>Trial Registration:</strong> ISRCTN67540073. Registered on 5 August 2015. 5 August 2015.</p> |
| first_indexed | 2024-03-06T22:14:18Z |
| format | Journal article |
| id | oxford-uuid:52e02803-300a-4378-8854-fc72c5f7080b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:14:18Z |
| publishDate | 2018 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:52e02803-300a-4378-8854-fc72c5f7080b2022-03-26T16:28:11ZEarly fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:52e02803-300a-4378-8854-fc72c5f7080bEnglishSymplectic ElementsBioMed Central2018Curry, NFoley, CWong, HMora, ACurnow, EZarankaite, AHodge, RHopkins, VDeary, ARay, JMoss, PReed, MJKellett, SDavenport, RStanworth, S<p><strong>Background:</strong><br /> There is increasing interest in the timely administration of concentrated sources of fibrinogen to patients with major traumatic bleeding. Following evaluation of early cryoprecipitate in the CRYOSTAT 1 trial, we explored the use of fibrinogen concentrate, which may have advantages of more rapid administration in acute haemorrhage. The aims of this pragmatic study were to assess the feasibility of fibrinogen concentrate administration within 45 minutes of hospital admission and to quantify efficacy in maintaining fibrinogen levels ≥ 2 g/L during active haemorrhage.</p><br /> <p><strong>Methods:</strong><br /> We conducted a blinded, randomised, placebo-controlled trial at five UK major trauma centres with adult trauma patients with active bleeding who required activation of the major haemorrhage protocol. Participants were randomised to standard major haemorrhage therapy plus 6 g of fibrinogen concentrate or placebo.</p><br /> <p><strong>Results:</strong><br /> Twenty-seven of 39 participants (69%; 95% CI, 52–83%) across both arms received the study intervention within 45 minutes of admission. There was some evidence of a difference in the proportion of participants with fibrinogen levels ≥ 2 g/L between arms (p = 0.10). Fibrinogen levels in the fibrinogen concentrate (FgC) arm rose by a mean of 0.9 g/L (SD, 0.5) compared with a reduction of 0.2 g/L (SD, 0.5) in the placebo arm and were significantly higher in the FgC arm (p < 0.0001) at 2 hours. Fibrinogen levels were not different at day 7. Transfusion use and thromboembolic events were similar between arms. All-cause mortality at 28 days was 35.5% (95% CI, 23.8–50.8%) overall, with no difference between arms.</p><br /> <p><strong>Conclusions:</strong><br /> In this trial, early delivery of fibrinogen concentrate within 45 minutes of admission was not feasible. Although evidence points to a key role for fibrinogen in the treatment of major bleeding, researchers need to recognise the challenges of timely delivery in the emergency setting. Future studies must explore barriers to rapid fibrinogen therapy, focusing on methods to reduce time to randomisation, using ‘off-the-shelf’ fibrinogen therapies (such as extended shelf-life cryoprecipitate held in the emergency department or fibrinogen concentrates with very rapid reconstitution times) and limiting the need for coagulation test-based transfusion triggers.</p><br /> <p><strong>Trial Registration:</strong> ISRCTN67540073. Registered on 5 August 2015. 5 August 2015.</p> |
| spellingShingle | Curry, N Foley, C Wong, H Mora, A Curnow, E Zarankaite, A Hodge, R Hopkins, V Deary, A Ray, J Moss, P Reed, MJ Kellett, S Davenport, R Stanworth, S Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial |
| title | Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial |
| title_full | Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial |
| title_fullStr | Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial |
| title_full_unstemmed | Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial |
| title_short | Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial |
| title_sort | early fibrinogen concentrate therapy for major haemorrhage in trauma e fit 1 results from a uk multi centre randomised double blind placebo controlled pilot trial |
| work_keys_str_mv | AT curryn earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT foleyc earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT wongh earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT moraa earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT curnowe earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT zarankaitea earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT hodger earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT hopkinsv earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT dearya earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT rayj earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT mossp earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT reedmj earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT kelletts earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT davenportr earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial AT stanworths earlyfibrinogenconcentratetherapyformajorhaemorrhageintraumaefit1resultsfromaukmulticentrerandomiseddoubleblindplacebocontrolledpilottrial |